PEGS Summit Europe Virtual 2020
Overview
PEGS Europe is the leading European event with comprehensive programming covering all aspects of protein and antibody engineering. Here are just some of the benefits of our virtual event:
View more presentations at your convenience as your Virtual registration includes On-Demand access
- View more presentations at your convenience as your Virtual registration includes On-Demand access
- You do not have to choose between multiple presentations taking place at the same time See unpublished data & case studies from leading researchers from industry & academia Reduced registration fees and no travel or hotel costs
- Connect with the right attendees based on mutual interests and expertise
- View 40+ virtual presentations from Top Biopharma
- See and hear your colleagues in facilitated networking Zoom rooms
- Integrated scheduling tool
- Virtual exhibit booths, posters, and networking roundtables
- Live chat and direct messaging
- Product directories
November 9-12, 2020
Register Fee- Premium Real-Time Virtual Pricing
- Premium Post-Event On-Demand Pricing
- Standard Real-Time Virtual Pricing
- Basic Real-Time Virtual Pricing
- Basic Post-Event On-Demand Pricing
- Register by 6 November to save up to €200
- https://chidb.com/reg/pge/reg.asp
www.pegsummiteurope.com
Contact chi@healthtech.com
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE